Vitamin D Management in Renal Dialysis Patients

Introduction to Vitamin D Therapy

The American Journal of Kidney Diseases recommends that dialysis patients with secondary hyperparathyroidism (PTH >300 pg/mL) should receive active vitamin D sterols (calcitriol, paricalcitol, or doxercalciferol) rather than nutritional vitamin D supplementation, with intermittent intravenous administration preferred over oral dosing for superior PTH suppression 1, 2

The American Journal of Kidney Diseases suggests verifying corrected serum calcium <9.5 mg/dL before initiating any vitamin D therapy 3
The American Journal of Kidney Diseases recommends verifying serum phosphorus <4.6 mg/dL before initiating any vitamin D therapy 4
The American Journal of Kidney Diseases advises to assess intact PTH level to guide therapy selection 1
The American Journal of Kidney Diseases recommends monitoring calcium and phosphorus every 2 weeks for the first month after initiation or dose adjustment, and then every 3 months after stabilization 1, 4
The American Journal of Kidney Diseases recommends monitoring PTH monthly for 3 months after initiation or dose adjustment, and then every 3 months after stabilization 1

For PTH 300-800 pg/mL, the American Journal of Kidney Diseases indicates that active vitamin D sterols are recommended (calcitriol, paricalcitol, or doxercalciferol) 1
For PTH >800 pg/mL, the American Journal of Kidney Diseases suggests considering parathyroidectomy if hypercalcemia and/or hyperphosphatemia are refractory to medical therapy 2, 5

For hemodialysis patients, the American Journal of Kidney Diseases recommends an initial dose (micrograms) = baseline iPTH (pg/mL) ÷ 80, administered three times weekly 1
For peritoneal dialysis patients, the American Journal of Kidney Diseases recommends oral calcitriol 0.5-1.0 mcg or doxercalciferol 2.5-5.0 mcg given 2-3 times weekly 1

The American Journal of Kidney Diseases states that nutritional vitamin D (ergocalciferol/cholecalciferol) has limited efficacy in dialysis patients because the kidneys cannot adequately convert 25(OH)D to active 1,25(OH)₂D 3, 6
If 25(OH)D levels are <30 ng/mL, the American Journal of Kidney Diseases recommends repleting with ergocalciferol 50,000 IU weekly for 12 weeks, then monthly 6, 7

The American Journal of Kidney Diseases advises never targeting normal PTH levels (<65 pg/mL) in dialysis patients, as this causes adynamic bone disease with increased fracture risk and inability to buffer calcium-phosphate loads 2
The American Journal of Kidney Diseases recommends never using calcitriol or active vitamin D sterols to treat nutritional vitamin D deficiency, but instead using ergocalciferol or cholecalciferol for this purpose 7
The American Journal of Kidney Diseases advises never starting active vitamin D therapy with phosphorus >4.6 mg/dL, but instead controlling phosphorus first with dietary restriction and phosphate binders 4, 2

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend initiating doxercalciferol when intact PTH exceeds 300 pg/mL in hemodialysis patients, targeting a therapeutic range of 150-300 pg/mL, but only after confirming serum calcium is within normal limits and serum phosphorus is controlled below 4.6 mg/dL 8
For patients with PTH 300-500 pg/mL, the American Journal of Kidney Diseases recommends initiating doxercalciferol at standard dosing 8
For patients with PTH 500-600 pg/mL, the American Journal of Kidney Diseases indicates that moderate to severe hyperparathyroid bone disease is typical, and treatment is clearly indicated 8
For patients with PTH >1,000 pg/mL, the American Journal of Kidney Diseases suggests that larger doses are generally required, and treatment duration may be longer to achieve target suppression 8

The K/DOQI guidelines recommend monitoring calcium and phosphorus weekly initially, or every 2 weeks for 1 month, then monthly, and monitoring PTH monthly for 3 months, then every 3 months once target is achieved 8
The American Journal of Kidney Diseases recommends alternative dosing for peritoneal dialysis patients, starting at 2.5-5.0 mcg given 2-3 times weekly 8
The American Journal of Kidney Diseases suggests that while doxercalciferol and paricalcitol demonstrate virtually identical mortality outcomes and similar efficacy in PTH suppression with minimal hypercalcemia risk compared to calcitriol, the choice between vitamin D analogs may be considered when calcium and phosphorus are above target range 8